Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 6.1% | 23.2% | -12% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99.8% | 99.8% | 99.7% | 100% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 5.8% | 1.3% | -39% | -19.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.1% | -7% | -43.5% | -26.4% |
| EPS Diluted | -0.067 | -0.14 | -0.71 | -0.49 |
| % Growth | 52.3% | 80.3% | -44.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |